v3.26.1
Revenue recognition - Collaboration and License Revenue (Details)
$ in Thousands
1 Months Ended 3 Months Ended 6 Months Ended
Jan. 31, 2025
USD ($)
Jun. 30, 2026
USD ($)
Jun. 30, 2025
USD ($)
Jun. 30, 2026
USD ($)
product
Jun. 30, 2025
USD ($)
Nov. 30, 2011
USD ($)
Revenue recognition            
Number of approved products | product       2    
Revenue   $ 360,519 $ 178,875 $ 633,070 $ 1,354,971  
Collaboration and license revenue            
Revenue recognition            
Revenue   50,595 2,941 50,738 989,172  
Royalty revenue            
Revenue recognition            
Revenue   71,105 57,605 117,940 94,044  
Novartis            
Revenue recognition            
Development milestone obligation revenue received       $ 50,000    
SMA License Agreement            
Revenue recognition            
Number of approved products | product       1    
SMA License Agreement | Collaboration and license revenue            
Revenue recognition            
Revenue   0 0 $ 0 0  
SMA License Agreement | Royalty revenue            
Revenue recognition            
Revenue   71,100 57,600 117,900 94,000  
License and Collaboration Agreement            
Revenue recognition            
Refund of revenue related to prior collaboration arrangements         3,500  
License and Collaboration Agreement | Novartis            
Revenue recognition            
Cash proceeds from upfront payment on collaboration agreement $ 1,000,000          
Percentage share of the income (loss) generated on U.S. sales 40.00%          
License and Collaboration Agreement | Novartis | Collaboration and license revenue            
Revenue recognition            
Revenue   50,600 $ 2,900 50,700 $ 992,700  
Research And Development Event Milestones | SMA License Agreement            
Revenue recognition            
Remaining potential milestones that can be achieved   0   0    
Sales Milestones | SMA License Agreement            
Revenue recognition            
Remaining potential milestones that can be achieved   $ 150,000   $ 150,000    
Maximum | License and Collaboration Agreement | Novartis            
Revenue recognition            
Potential future proceeds contingent on achievement of developmental, regulatory and sales milestones and tiered royalties $ 1,900,000          
Maximum | Research And Development Event Milestones | SMA License Agreement            
Revenue recognition            
Remaining potential milestones that can be achieved           $ 135,000
Maximum | Sales Milestones | SMA License Agreement            
Revenue recognition            
Remaining potential milestones that can be achieved           $ 325,000